121 related articles for article (PubMed ID: 38603653)
1. Erratum: Regorafenib in Patients With Solid Tumors With
JCO Precis Oncol; 2024 Apr; 8():e2400121. PubMed ID: 38603653
[No Abstract] [Full Text] [Related]
2. Regorafenib in Patients With Solid Tumors With
Sahai V; Rothe M; Mangat PK; Garrett-Mayer E; Suhag V; Dib EG; Mehmi I; Kadakia KC; Pisick E; Duvivier HL; Le P; Li R; Michelin DP; Wilcox RE; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Apr; 8():e2300527. PubMed ID: 38603652
[TBL] [Abstract][Full Text] [Related]
3. Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Mangat PK; Halabi S; Bruinooge SS; Garrett-Mayer E; Alva A; Janeway KA; Stella PJ; Voest E; Yost KJ; Perlmutter J; Pinto N; Kim ES; Schilsky RL
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30603737
[TBL] [Abstract][Full Text] [Related]
4. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Fisher JG; Tait D; Garrett-Mayer E; Halabi S; Mangat PK; Schink JC; Alvarez RH; Veljovich D; Cannon TL; Crilley PA; Pollock T; Calfa CJ; Al Baghdadi T; Thota R; Fleming N; Cotta JA; Rygiel AL; Warren SL; Schilsky RL
Target Oncol; 2020 Dec; 15(6):733-741. PubMed ID: 33090333
[TBL] [Abstract][Full Text] [Related]
6. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With
Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Alva AS; Mangat PK; Garrett-Mayer E; Halabi S; Hansra D; Calfa CJ; Khalil MF; Ahn ER; Cannon TL; Crilley P; Fisher JG; Haslem DS; Shrestha S; Antonelli KR; Butler NL; Warren SL; Rygiel AL; Ranasinghe S; Bruinooge SS; Schilsky RL
J Clin Oncol; 2021 Aug; 39(22):2443-2451. PubMed ID: 33844595
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Al Baghdadi T; Garrett-Mayer E; Halabi S; Mangat PK; Rich P; Ahn ER; Chai S; Rygiel AL; Osayameh O; Antonelli KR; Islam S; Bruinooge SS; Schilsky RL
Target Oncol; 2020 Dec; 15(6):743-750. PubMed ID: 33068284
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib in Patients With Pancreatic and Biliary Cancer With
Al Baghdadi T; Halabi S; Garrett-Mayer E; Mangat PK; Ahn ER; Sahai V; Alvarez RH; Kim ES; Yost KJ; Rygiel AL; Antonelli KR; Butler NL; Bruinooge SS; Schilsky RL
JCO Precis Oncol; 2019 Dec; 3():1-8. PubMed ID: 35100714
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib in Patients With Non-Small-Cell Lung Cancer With
Ahn ER; Mangat PK; Garrett-Mayer E; Halabi S; Dib EG; Haggstrom DE; Alguire KB; Calfa CJ; Cannon TL; Crilley PA; Gaba AG; Marr AS; Sangal A; Thota R; Antonelli KR; Islam S; Rygiel AL; Bruinooge SS; Schilsky RL
JCO Precis Oncol; 2020 Nov; 4():757-766. PubMed ID: 35050752
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Duvivier HL; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Al Baghdadi T; Alva AS; Dublis SA; Cannon TL; Calfa CJ; Li R; Behl D; Chiu VK; Gold PJ; Marr AS; Mileham KF; Powell SF; Rodon J; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
J Clin Oncol; 2023 Nov; 41(33):5140-5150. PubMed ID: 37561967
[TBL] [Abstract][Full Text] [Related]
13. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
14. Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.
Hilhorst R; van den Berg A; Boender P; van Wezel T; Kievits T; de Wijn R; Ruijtenbeek R; Corver WE; Morreau H
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760447
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry.
Alawawdeh A; Price T; Karapetis C; Piantadosi C; Padbury R; Roy A; Maddern G; Moore J; Carruthers S; Roder D; Townsend AR
Asia Pac J Clin Oncol; 2022 Aug; 18(4):428-433. PubMed ID: 34811937
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.
Yan Y; Grothey A
Onco Targets Ther; 2015; 8():2949-57. PubMed ID: 26508880
[TBL] [Abstract][Full Text] [Related]
17. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
20. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
